サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1692299

子宮頸がん診断市場- 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、エンドユーザー別、地域別、競合別、2020-2030F

Cervical Cancer Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End User, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

子宮頸がん診断市場- 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、エンドユーザー別、地域別、競合別、2020-2030F
出版日: 2025年03月24日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

子宮頸がん診断の世界市場は、2024年に82億7,000万米ドルと評価され、予測期間中のCAGRは6.24%で、2030年には118億9,000万米ドルに達すると予測されています。

中年層の女性における子宮頸がん罹患率の上昇は、スクリーニング検査や診断検査の需要増加により、今後数年間の市場成長を牽引すると予測されます。世界保健機関（WHO）の発表によると、子宮頸がんは世界の女性の間で4番目に罹患率の高いがんと位置づけられています。さらに、2023年の米国がん協会のデータによると、米国では浸潤性子宮頸がんが約13,960例診断され、約4,310人の女性が死亡すると推定されています。

市場概要
予測期間 2026-2030
市場規模：2024年 82億7,000万米ドル
市場規模：2030年 118億9,000万米ドル
CAGR：2025年～2030年 6.24%
急成長セグメント パップテスト
最大市場 北米

市場促進要因

意識の高まりと教育

主な市場課題

ヘルスケア不公平

主要市場動向

分子診断革命

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の子宮頸がん診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 検査の種類別（パップテスト、HPV検査、膣鏡検査、子宮頸部生検、膀胱鏡検査）
    • エンドユーザー別（病院・診療所、診断研究所、その他）
    • 地域別
    • 企業別（2024）
  • 製品市場マップ
    • テストタイプ別
    • 最終用途別
    • 地域別

第6章 北米の子宮頸がん診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の子宮頸がん診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン

第8章 アジア太平洋地域の子宮頸がん診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国

第9章 南米の子宮頸がん診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの子宮頸がん診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収
  • 製品上市

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Becton Dickinson and Company
  • Hologic Inc
  • CooperSurgical Inc
  • Siemens Healthineers AG
  • Quigan NV
  • F. Hoffmann-La Roche Ltd
  • Oncgnostics GmbH
  • Quest Diagnostics

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 20916

Global Cervical Cancer Diagnostic Market was valued at USD 8.27 billion in 2024 and is expected to reach USD 11.89 billion by 2030 with a CAGR of 6.24% during the forecast period. The rise in cervical cancer rates among women in the middle age bracket is anticipated to drive market growth in the coming years due to the increased demand for screening and diagnostic tests. According to the World Health Organization's publications, cervical cancer is ranked as the fourth most prevalent cancer among women worldwide. Additionally, according to data from the American Cancer Society in 2023, it is estimated that approximately 13,960 cases of invasive cervical cancer will be diagnosed, resulting in approximately 4,310 female fatalities in the United States.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 8.27 Billion
Market Size 2030USD 11.89 Billion
CAGR 2025-20306.24%
Fastest Growing SegmentPap testing
Largest MarketNorth America

Key Market Drivers

Rising Awareness and Education

Cervical cancer is a formidable global health challenge, but increasing awareness and education are proving to be powerful catalysts for growth in the Global Cervical Cancer Diagnostic Market. The recognition of the importance of early detection and regular screenings is essential for reducing the burden of this disease. Awareness campaigns, educational programs, and advocacy efforts have been instrumental in empowering women with knowledge about cervical cancer and its prevention. These initiatives disseminate information about the disease, its risk factors, and the significance of regular screenings. As women become more informed, they are more likely to take proactive steps toward their health, including undergoing cervical cancer diagnostics.

Awareness and education campaigns stress the importance of early detection. Women who understand the benefits of regular screenings are more likely to schedule appointments with healthcare providers. This increased demand for screening services directly contributes to the growth of the cervical cancer diagnostic market. Cervical cancer screenings, such as Pap smears, can be intimidating for many women due to fear or discomfort. However, informed women are more likely to overcome these fears, knowing that early detection can be life-saving. Reducing the stigma and fear associated with cervical cancer diagnostics encourages more women to seek these services, further boosting market growth.

Key Market Challenges

Healthcare Inequity

Healthcare disparities exist in many parts of the world, and cervical cancer diagnostic services are not exempt from these inequalities. Women in marginalized communities often face barriers such as limited financial resources, lack of transportation, and inadequate healthcare infrastructure, which restrict their access to screening services.

Key Market Trends

Molecular Diagnostics Revolution

Molecular diagnostic techniques, including nucleic acid testing, have gained prominence in cervical cancer diagnosis. These methods offer increased sensitivity and specificity in detecting human papillomavirus (HPV) infections and identifying specific viral strains associated with cervical cancer. The trend is moving towards molecular testing becoming a standard procedure in cervical cancer screening, enabling more precise diagnoses.

Key Market Players

  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Becton Dickinson and Company
  • Hologic Inc
  • CooperSurgical Inc
  • Siemens Healthineers AG
  • Quigan NV
  • F. Hoffmann-La Roche Ltd
  • Oncgnostics GmbH
  • Quest Diagnostics

Report Scope:

In this report, the Global Cervical Cancer Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cervical Cancer Diagnostic Market, By Test Type:

  • Pap testing
  • HPV testing
  • Colposcopy
  • Cervical biopsies
  • Cystoscopy

Cervical Cancer Diagnostic Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Cervical Cancer Diagnostic Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cervical Cancer Diagnostic Market.

Available Customizations:

Global Cervical Cancer Diagnostic market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cervical Cancer Diagnostic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 5.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Test Type
    • 5.3.2. By End Use
    • 5.3.3. By Region

6. North America Cervical Cancer Diagnostic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 6.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cervical Cancer Diagnostic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Cervical Cancer Diagnostic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Cervical Cancer Diagnostic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By End Use

7. Europe Cervical Cancer Diagnostic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 7.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cervical Cancer Diagnostic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By End Use
    • 7.3.2. United Kingdom Cervical Cancer Diagnostic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By End Use
    • 7.3.3. France Cervical Cancer Diagnostic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Cervical Cancer Diagnostic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Cervical Cancer Diagnostic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By End Use

8. Asia-Pacific Cervical Cancer Diagnostic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 8.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cervical Cancer Diagnostic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By End Use
    • 8.3.2. Japan Cervical Cancer Diagnostic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By End Use
    • 8.3.3. India Cervical Cancer Diagnostic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By End Use
    • 8.3.4. Australia Cervical Cancer Diagnostic Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By End Use
    • 8.3.5. South Korea Cervical Cancer Diagnostic Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By End Use

9. South America Cervical Cancer Diagnostic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 9.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cervical Cancer Diagnostic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Cervical Cancer Diagnostic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Cervical Cancer Diagnostic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Cervical Cancer Diagnostic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 10.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cervical Cancer Diagnostic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Cervical Cancer Diagnostic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Cervical Cancer Diagnostic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By End Use
    • 10.3.4. Kuwait Cervical Cancer Diagnostic Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Test Type
        • 10.3.4.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.2. Product Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Thermo Fisher Scientific Inc
  • 14.3. Becton Dickinson and Company
  • 14.4. Hologic Inc
  • 14.5. CooperSurgical Inc
  • 14.6. Siemens Healthineers AG
  • 14.7. Quigan NV
  • 14.8. F. Hoffmann-La Roche Ltd
  • 14.9. Oncgnostics GmbH
  • 14.10. Quest Diagnostics

15. Strategic Recommendations

16. About Us & Disclaimer